Shots:

• The P-III program involves assessing of Roxadustat vs PBO and epoetin alfa in 9-000+ NDD and DD & ID patients in multiple studies conducted by AstraZeneca- FibroGen and Astellas together globally respectively
• Results: The risk of MACE- MACE+ and all-cause mortality & Hb level (1.85 g/dL vs 0.13 g/dL) in NDD patients was comparable to PBO- showed 30% lower risk of MACE and 34% lower risk of MACE+ with a trend towards lower all-cause mortality in ID patients- no increased risk of MACE and all-cause mortality and a lower risk of MACE+- Hb level (1.22 g/dL vs 0.99 g/dL) in DD patients
• Roxadustat is a first-in-class- hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being evaluated for the treatment of anaemia in CKD. The results from pooled analysis served as a basis for its anticipated regulatory submission in the US in Q4’19

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca